year
elaps
sinc
sever
acut
respiratori
syndrom
sar
trigger
first
global
alert
coronaviru
infect
viru
transmiss
human
quickli
halt
public
health
measur
human
infect
sar
coronaviru
sarscov
observ
sinc
howev
coronavirus
still
pose
continu
threat
human
health
exemplifi
recent
emerg
middl
east
respiratori
syndrom
mer
human
work
sarscov
widen
knowledg
epidemiolog
pathophysiolog
immunolog
coronavirus
may
shed
light
mer
coronaviru
merscov
confirm
tcell
immun
play
import
role
recoveri
sarscov
infect
herein
summar
tcell
immunolog
studi
sarscov
discuss
potenti
crossreact
sarscovspecif
immun
merscov
may
provid
use
recommend
develop
broadspectrum
vaccin
coronaviru
infect
success
control
spread
sever
acut
respiratori
syndrom
coronaviru
sarscov
facilit
establish
intern
collabor
system
infecti
diseas
prevent
control
process
larg
number
studi
perform
focus
epidemiolog
pathophysiolog
immunolog
vaccin
develop
structur
studi
sarscov
studi
help
widen
knowledg
sarscov
whole
coronaviru
famili
well
promot
methodolog
studi
virus
almost
ten
year
emerg
sar
novel
coronaviru
term
middl
east
respiratori
syndrom
coronaviru
merscov
first
report
middl
east
zaki
et
al
viru
found
respons
outbreak
acut
respiratori
ill
public
hospit
zarqa
jordan
april
hijawi
et
al
import
case
sinc
report
franc
germani
itali
tunisia
unit
state
unit
kingdom
su
et
al
wong
et
al
outbreak
merscov
report
south
korea
death
confirm
case
http
wwwwhointemergenciesmerscoven
one
patient
travel
south
korea
china
repres
first
case
merscov
china
su
et
al
clinic
featur
patient
infect
merscov
similar
sar
ie
sever
pneumonia
feng
gao
zaki
et
al
sarscovlik
virus
discov
insectivor
rhinolophid
bat
virus
genet
relat
merscov
also
detect
neoromicia
capensi
bat
africa
corman
et
al
lau
et
al
li
et
al
recent
bat
origin
merscov
support
evid
bat
coronaviru
also
use
human
merscov
receptor
viru
entri
addit
merscovlik
virus
also
widespread
dromedari
camel
seroepidemiolog
studi
indic
seropreval
adult
anim
reusken
et
al
pivot
role
virusspecif
memori
tcell
broad
longterm
protect
sarscov
infect
elucid
zhao
et
al
inde
crucial
protect
role
tcell
immun
respons
coronaviru
infect
clearli
document
sever
anim
model
eg
felin
infecti
periton
viru
fipv
mous
hepat
viru
mhv
avian
infecti
bronchiti
viru
ibv
takano
et
al
trujillo
et
al
anim
model
provid
use
refer
studi
human
infect
sarscov
merscov
infect
mice
mhv
member
betacoronaviru
group
sarscov
merscov
use
earli
experiment
model
elucid
role
tcell
viral
clearanc
cytotox
le
prevost
et
al
tcell
orient
vaccin
develop
macnamara
et
al
zust
et
al
primari
role
cytotox
lymphocyt
ctl
demonstr
protect
mhv
viru
clearanc
stohlman
et
al
review
focu
lesson
learn
tcell
immunolog
studi
sarscov
includ
immunogen
sarscov
structur
protein
tcell
epitop
identifi
tcellori
vaccin
develop
structur
immunolog
sarscov
base
human
leucocyt
antigen
class
hla
peptid
structur
hilgenfeld
peiri
base
knowledg
tcell
immun
sar
recent
studi
mer
immun
correl
potenti
tcell
crossreact
sarscov
merscov
evalu
may
implic
vaccin
develop
human
coronaviru
infect
natur
infect
sarscov
give
rise
domin
respons
structur
antigen
sarscov
human
anim
spike
protein
respons
receptor
bind
membran
fusion
viru
also
act
major
antigen
humor
cellular
immun
du
et
al
xu
colleagu
detect
sarscovspecif
tcell
respons
peripher
blood
mononuclear
cell
pbmc
convalesc
sar
patient
use
overlap
peptid
cover
whole
sarscov
proteom
found
antigen
peptid
locat
structur
protein
especi
protein
rather
nonstructur
protein
bias
distribut
tcell
epitop
viral
protein
may
correl
differ
protein
synthesi
phase
infect
divers
abund
viral
protein
infect
cell
antigenpres
cell
nucleocapsid
n
protein
sarscov
also
trigger
antibodi
tcell
respons
human
though
neutral
protect
activ
antibodiestcel
still
need
defin
leung
et
al
lin
et
al
woo
et
al
membran
protein
abund
protein
sarscov
virion
also
act
domin
immunogen
reveal
cluster
region
blymphocyt
ctl
epitop
liu
et
al
dozen
tcell
specif
epitop
deriv
sarscov
structur
protein
identifi
divers
strategi
past
year
tabl
review
report
concern
tcell
specif
immunolog
sarscov
collect
tcell
epitop
defin
sinc
initi
sar
outbreak
fig
among
tcell
epitop
tabl
peptid
identifi
thu
far
deriv
protein
restrict
consequ
immunodomin
sarscov
protein
high
coverag
popul
differ
ethnic
group
world
hlaa
hlaa
hlab
hlab
tcell
epitop
also
defin
use
detect
tcell
immun
respons
among
popul
oh
et
al
also
sever
k
b
restrict
tcell
tcell
epitop
identifi
use
differ
mous
strain
help
sarscovspecif
tcell
studi
among
anim
model
develop
vaccin
zhao
et
al
zhi
et
al
given
cell
epitop
identifi
thu
far
deriv
sarscov
protein
epitop
discoveri
still
need
especi
structur
protein
base
effici
tcell
epitop
screen
platform
combin
bioinformat
cell
biolog
mous
model
tabl
sarscovderiv
tcell
epitop
conserv
human
coronavirus
posit
inform
base
sarscov
strain
tjf
genbank
access
b
sequenc
correspond
peptid
sarscov
strain
genbank
access
strain
genbank
access
variabl
residu
peptid
compar
merscov
underlin
bold
c
refer
identifi
peptid
refer
use
peptid
vaccin
use
peptid
evalu
sarsrel
vaccin
e
posit
hlarestrict
peptid
three
less
variabl
residu
merscov
three
coronavirus
sarscov
shown
bold
structur
biolog
liu
et
al
sever
tcellspecif
epitop
deriv
sarscov
protein
identifi
group
zhou
et
al
interestingli
also
defin
cluster
region
ctl
epitop
within
transmembran
region
protein
fig
liu
et
al
may
correl
sequenc
prefer
peptideprocess
relat
protein
transport
associ
antigen
process
tap
immunoproteasom
tap
bind
protein
tapasin
protein
transmembran
region
usual
rich
aliphat
amino
acid
eg
leu
ile
val
prefer
primari
anchor
residu
peptid
sharp
et
al
work
need
elucid
whether
protein
good
candid
antigen
prophylact
vaccin
induc
cellular
humor
immunogen
also
identifi
first
immunodomin
tcell
epitop
sarscov
n
protein
recent
sever
merscovderiv
restrict
tcell
epitop
identifi
tcell
respons
one
newli
defin
peptid
peptid
protect
effect
merscov
challeng
protect
effici
peptid
depend
uncommon
interact
peptid
host
mhc
tcell
epitop
differ
hlairestrict
also
tcell
epitop
screen
platform
may
help
understand
tcell
immunogen
differ
protein
coronavirus
provid
potenti
candid
vaccin
develop
welldefin
antigen
peptid
act
use
agent
studi
sarsspecif
immun
immunopathogenesi
importantli
candid
vaccin
develop
major
antigen
tcelltarget
vaccin
focus
n
protein
sarscov
due
low
immunogen
singl
peptid
vaccin
mani
differ
strategi
develop
elicit
effect
tcell
respons
effici
protect
tcellbas
vaccin
dna
vaccin
encod
n
gene
segment
cover
immunodomin
tcell
epitop
develop
mous
model
cheung
et
al
produc
potenti
dna
vaccin
candid
express
antigen
peptid
sarscov
n
protein
singlechaintrim
peptideb
mmhc
approach
induc
sarscovspecif
tcell
cytotox
n
proteinexpress
cell
cheung
et
al
recombin
adenoassoci
viru
also
ideal
carrier
tcell
immunogen
sarscov
induc
strong
mucos
immun
respons
protect
ctl
respons
du
et
al
mammalian
cho
cellsexpress
segment
sarscov
protein
also
induc
potent
tcell
immun
respons
protect
viru
du
et
al
du
et
al
zhao
colleagu
observ
enhanc
virusspecif
tcell
mice
immun
sarscov
peptidepuls
dendrit
cell
also
result
earlier
viru
clearanc
increas
surviv
zhao
et
al
phase
clinic
trial
singleplasmid
dna
vaccin
encod
protein
well
toler
induc
sarscovspecif
tcell
respons
vaccine
well
tcell
respons
individu
martin
et
al
mhc
iirel
antigen
present
profession
antigenpres
cell
may
involv
domin
tcell
respons
dna
vaccin
requir
neutral
antibodi
though
crossprim
stimul
tcell
also
occur
akbari
et
al
differ
adjuv
investig
increas
efficaci
peptid
vaccin
surfacelink
liposom
peptid
muramyl
dipeptid
deriv
adjuv
chen
et
al
cpg
oligodeoxynucleotid
cpg
odn
zhao
et
al
augment
peptidespecif
tcell
respons
protect
du
et
al
du
et
al
du
et
al
zhao
et
al
durabl
du
et
al
kohyama
et
al
yang
et
al
viruslik
particl
vlp
vaccin
contain
protein
domin
immunogen
adjuv
aluminum
provid
protect
mice
challeng
sarscov
liu
et
al
lokugamag
et
al
studi
demonstr
cell
play
crucial
role
sarscov
clearanc
elucid
avenu
vaccin
develop
human
coronavirus
includ
merscov
du
et
al
wang
et
al
howev
sarscov
vaccin
led
occurr
immunopatholog
spite
antibodi
protect
infect
sarscov
mice
tseng
et
al
therefor
applic
sarscov
vaccin
human
proceed
caution
sinc
outbreak
sarscov
kinet
primari
memori
immun
respons
sarscov
infect
investig
patient
survivor
mileston
studi
present
fig
igg
n
protein
detect
sera
earli
day
ill
onset
base
immunofluoresc
assay
elisa
patient
seroconvert
day
hsueh
et
al
igg
neutral
antibodi
peak
month
progress
decreas
time
liu
et
al
eightynin
percent
recov
patient
detect
igg
antibodi
sarscov
month
postinfect
shown
elisa
neutral
antibodi
detect
even
higher
percentag
donor
liu
et
al
nevertheless
diseas
sever
may
also
impact
appear
time
magnitud
antibodi
respons
cameron
colleagu
report
sarscovinfect
patient
fatal
outcom
display
defici
antibodi
product
protein
compar
nonsever
patient
cameron
et
al
long
term
followup
sar
survivor
igg
detect
recov
donor
year
ill
onset
tang
et
al
suggest
diminish
level
memori
bcell
sarscov
laboratori
investig
clinic
patient
demonstr
sarscovspecif
tcell
import
recognit
clearanc
infect
cell
particularli
lung
infect
individu
gu
et
al
although
whether
memori
tcell
respons
suffici
protect
reinfect
requir
investig
suggest
robust
ctl
respons
contribut
protect
sarscov
mice
chen
et
al
zhao
et
al
base
seri
tcell
epitop
identifi
thu
far
well
overlap
peptid
pool
cover
fulllength
antigen
sarscov
durabl
memori
tcell
respons
sarscov
evalu
recov
patient
chen
et
al
fan
et
al
peng
et
al
yang
et
al
yang
et
al
unlik
wane
serum
antibodi
level
patient
ctl
respons
n
protein
still
detect
pbmc
recov
sar
patient
even
year
postinfect
da
guan
et
al
ng
et
al
oh
et
al
tang
et
al
find
expect
implic
diseas
surveil
potenti
crossreact
coronavirus
knowledg
adapt
immun
merscov
also
base
recent
clinic
data
laboratori
investig
specimen
mer
patient
south
korea
min
et
al
park
et
al
china
da
guan
et
al
wang
et
al
unit
state
kapoor
et
al
kingdom
saudi
arabia
corman
et
al
seroconvers
patient
occur
second
third
week
symptom
onset
corman
et
al
park
et
al
wang
et
al
similar
sar
patient
weak
delay
antibodi
respons
associ
sever
diseas
fatal
outcom
patient
infect
merscov
corman
et
al
min
et
al
park
et
al
howev
corman
colleagu
corman
et
al
discov
level
igg
neutral
antibodi
weakli
invers
correl
viral
load
lower
respiratori
tract
suggest
presenc
antibodi
lead
elimin
viru
merscovspecif
tcell
respons
pbmc
obtain
day
ill
onset
show
strong
specif
tcell
respons
merscov
protein
da
guan
et
al
interestingli
persist
gradual
increas
lymphocyt
respons
symptom
onset
mer
patient
without
mild
pneumonia
may
requir
effect
immun
respons
merscov
wherea
deceas
patient
display
rapid
drop
lymphocyt
count
min
et
al
tcell
immunityassoci
cytokin
ifng
level
lower
fatal
case
patient
surviv
infect
faur
et
al
seven
previous
unconfirm
individu
test
posit
merscovspecif
antibodi
month
mer
outbreak
jordanian
hospit
indic
antibodi
persist
least
year
asymptomat
case
alabdallat
et
al
howev
longitudin
studi
mer
survivor
jeddah
saudi
arabia
two
nine
survivor
remain
posit
mersspecif
antibodi
test
month
ill
onset
alshukairi
et
al
furthermor
arabi
colleagu
arabi
et
al
report
healthcar
worker
histori
laboratoryconfirm
merscov
infect
detect
merscovantibodi
level
elisa
median
day
infect
data
indic
merscovantibodi
level
declin
rapidli
compar
sarscov
survivor
thu
valuabl
investig
featur
tcell
immun
merscov
survivor
may
shed
light
merscov
vaccin
develop
longterm
protect
futur
structur
proteom
studi
virus
sarscov
hiv
influenza
viru
reveal
seri
import
antibodyrecogn
epitop
major
surfac
antigen
indic
bcellspecif
antigen
featur
julien
et
al
li
et
al
zhou
et
al
herein
summar
structur
characterist
sarscovspecif
tcell
epitop
present
hla
molecul
recogn
tcell
receptor
includ
structur
three
hlaa
one
hlaa
one
hlaa
one
hlab
molecul
blicher
et
al
liu
et
al
liu
et
al
liu
et
al
roder
et
al
structur
determin
sarscovderiv
peptidehla
complex
provid
corrobor
evid
tcell
epitop
identif
base
unambigu
electron
densiti
anchor
residu
hla
ibound
peptid
conclud
whether
peptid
question
typic
hla
irestrict
epitop
similar
hla
molecul
major
anchor
residu
second
nterminu
last
posit
peptid
structur
hla
complex
sarscov
peptid
interestingli
previous
identifi
two
epitop
tlacfvlaav
ctermin
truncat
peptid
lacfvlaav
liu
et
al
liu
et
al
base
structur
determin
two
peptid
complex
hlaa
found
use
differ
residu
primari
anchor
posit
though
ctermin
anchor
peptid
insert
b
pocket
hlaa
anchor
peptid
correspond
solventexpos
conform
two
peptid
complet
distinct
indic
two
peptid
may
function
independ
epitop
correspond
differ
specif
tcell
repertoir
structur
tcell
epitop
sarscov
n
protein
complex
hlaa
determin
novel
immunodomin
peptid
present
strategi
structur
hlaa
complex
peptid
main
chain
central
region
exist
moder
bulg
conform
stabil
two
intrachain
hydrogen
bond
two
water
molecul
peptid
bind
groov
featur
shape
conform
caus
three
residu
central
region
bulg
hlaa
surfac
potenti
tcell
receptor
tcr
dock
fig
hla
ipeptid
complex
structur
hold
inform
necessari
direct
approach
peptidebas
vaccin
design
exampl
structur
hlaa
peptid
blicher
et
al
make
effici
use
e
pocket
hlaa
groov
thu
potenti
target
optim
develop
peptid
vaccin
sarscov
residu
differ
posit
peptid
play
distinct
role
hla
ibind
tcr
dock
thu
structur
studi
hla
ipeptid
complex
direct
visibl
implic
tcell
antigen
variabl
close
relat
peptid
within
differ
virus
base
structur
tcell
epitop
deriv
sarscov
antigen
variabl
merscov
compar
sarscov
ration
analyz
sinc
merscov
belong
genu
betacoronaviru
sarscov
necessari
investig
whether
immun
respons
induc
sarscov
crossreact
merscov
chan
colleagu
conduct
seropreval
studi
archiv
sera
use
indirect
immunofluoresc
screen
confirmatori
neutral
antibodi
test
sar
patient
southern
china
antisarscov
neutral
antibodi
sarscov
found
major
sar
patient
expect
seventeen
sar
patient
test
posit
merscovspecif
igg
detect
indirect
titer
rang
seven
low
titer
less
merscov
neutral
antibodi
howev
subsequ
studi
show
absenc
crossreact
sarscov
merscov
du
et
al
meyer
et
al
reusken
et
al
du
colleagu
discov
seri
sarscov
receptor
bind
domain
rbd
specif
monoclon
antibodi
mab
serum
polyclon
antibodi
sarscov
srbd
vaccin
individu
crossreact
neutral
merscov
du
et
al
base
sequenc
analysi
fig
amino
acid
ident
protein
rbd
merscov
sarscov
respect
may
explain
observ
low
crossneutr
activ
howev
protein
sequenc
ident
region
protein
merscov
sarscov
respons
viru
fusion
cell
wherea
ident
n
e
protein
respect
suggest
may
potenti
crosstcel
reactiv
merscov
sarscov
analysi
known
tcell
epitop
deriv
sarscov
show
hla
allelerestrict
epitop
locat
region
protein
n
protein
conserv
fig
tabl
furthermor
three
peptid
region
protein
two
n
protein
one
protein
merscov
two
three
variabl
residu
align
correspond
sequenc
sarscov
among
six
peptid
glmwlsyfv
protein
amino
acid
sarscov
previous
identifi
immunodomin
tcell
epitop
base
combin
function
structur
strategi
liu
et
al
correspond
peptid
ammwisyfv
protein
merscov
three
differ
residu
structur
peptid
present
hlaa
fig
show
residu
locat
b
pocket
hlaa
respect
anchor
residu
correspond
residu
merscovderiv
peptid
also
act
anchor
residu
may
influenc
conform
peptid
bind
hlaa
solventexpos
residu
peptid
sarscov
correspond
ile
merscov
consid
similar
characterist
leu
ile
chang
may
limit
influenc
tcr
bind
peptid
thu
peptid
sarscov
parallel
peptid
merscov
may
crosstcr
repertoir
experiment
valid
recent
studi
rel
conserv
cell
epitop
fig
also
recogn
sarscovand
merscovinfect
transgen
mice
indic
vaccin
strategi
target
conserv
epitop
may
broadli
applic
differ
coronavirus
conserv
correspond
peptid
among
human
coronavirus
hcov
shown
tabl
conserv
tcell
epitop
exist
among
differ
hcov
instanc
peptid
sarscov
litgrlqsl
restrict
tcell
epitop
correspond
peptid
among
merscov
lingrlttl
hcov
lingrlttl
lingrlttl
one
variabl
residu
posit
glmwlsyfv
sarscov
correspond
peptid
hcov
iimwivyfv
iviwilyfv
still
typic
anchor
residu
data
may
also
indic
prior
infect
may
also
crossprotect
merscov
sarscov
consid
common
exist
crossreact
sequencerel
viru
epitop
would
import
topic
experiment
investig
da
guan
colleagu
da
guan
et
al
found
healthcar
worker
infect
sarscov
year
ago
still
detect
respons
sarscov
protein
lowlevel
crosstcel
respons
merscov
protein
interestingli
base
pbmc
obtain
travel
guangdong
china
acquir
diseas
mer
outbreak
south
korea
strong
tcellspecif
respons
fulllength
merscov
protein
detect
crossreact
subunit
sarscov
protein
may
due
low
level
conserv
subunit
discuss
may
also
correl
low
efficaci
stimul
tcell
respons
recombin
protein
function
sarscov
receptor
play
critic
role
sarscovinduc
lung
injuri
kuba
et
al
inject
sarscov
protein
wildtyp
mice
worsen
acut
lung
failur
vivo
block
reninangiotensin
pathway
downregul
express
signific
patholog
featur
appear
mice
chang
lung
parenchyma
increas
lung
edema
contrast
treatment
protein
affect
sever
lung
failur
knockout
mice
indic
effect
protein
acut
lung
injuri
merscov
receptor
dipeptidyl
peptidas
also
name
raj
et
al
interact
vivo
natur
ligand
adenosin
deaminas
ada
play
crucial
role
glucos
metabol
like
tcell
activ
chemotaxi
modul
cell
adhes
apoptosi
morimoto
schlossman
recent
structur
studi
rbd
merscov
protein
complex
indic
potenti
competit
bind
merscov
protein
instead
ada
impli
influenc
merscov
infect
pathogenesi
via
receptor
similar
sarscov
infect
recent
chu
colleagu
demonstr
merscov
effici
infect
tcell
peripher
blood
human
lymphoid
organ
includ
spleen
tonsil
induc
apoptosi
tcell
chu
et
al
howev
whether
interact
merscov
protein
cellular
receptor
involv
process
requir
explor
inde
efficaci
antivir
therapi
base
mab
merscov
corti
et
al
li
et
al
tang
et
al
may
relat
direct
neutral
virion
blockag
intervent
function
protein
viru
pathogenesi
studi
sarscov
elucid
divers
strategi
use
viru
evad
block
host
immun
respons
facilit
infect
transmiss
sar
mous
model
demonstr
lethal
pneumonia
contribut
dysregul
type
interferon
inflammatori
monocytemacrophag
respons
recent
studi
indic
merscov
also
evolv
specif
interferon
antagonist
counteract
innat
immun
respons
niemey
et
al
yang
et
al
zhou
et
al
serum
ifna
level
elev
fatal
case
compar
patient
recov
infect
faur
et
al
similar
strategi
develop
evadeinhibit
host
innat
immun
function
sarscov
merscov
vijay
perlman
inhibit
interferon
signal
sarscovinfect
cell
inhibit
phosphoryl
jauregui
et
al
inhibit
host
gene
express
inactiv
translat
activ
ribosom
interact
inhibit
phosphoryl
dimer
nuclear
transloc
render
viral
rna
indistinguish
host
tcell
rna
effect
methyl
frieman
et
al
menacheri
et
al
n
protein
inhibit
nfkb
signal
pkr
function
kopeckybromberg
et
al
similar
immun
evas
strategi
share
sarscov
merscov
may
indic
common
therapeut
target
drug
develop
thu
far
merscov
vaccin
shown
provid
efficaci
protect
anim
model
though
none
vaccin
develop
test
human
clinic
trial
major
strategi
vaccin
develop
focus
elicit
serum
antibodi
major
antigen
protein
merscov
passiv
immunotherapi
use
convalesc
phase
human
plasma
consid
mer
patient
success
anim
model
howev
studi
also
demonstr
merscov
proteinderiv
vaccin
induc
specif
tcell
virusneutr
antibodi
could
contribut
complet
protect
merscov
anim
model
lan
et
al
volz
et
al
base
investig
immun
memori
sarscov
followup
studi
recov
patient
discuss
tcell
respons
provid
robust
longterm
memori
possess
consider
potenti
crossreact
heterotyp
coronavirus
thu
vaccin
combin
cellular
humor
respons
consid
coronaviru
prevent
similar
immunopathogenesi
sarscov
merscov
interact
cell
receptor
blockag
host
innat
immun
respons
also
point
potenti
therapeut
target
patient
infect
pathogen
coronavirus
work
support
grant
china
megaproject
infecti
diseas
prevent
grant
nation
project
china
ministri
scienc
technolog
grant
nation
natur
scienc
foundat
china
grant
funder
role
studi
design
data
collect
interpret
decis
submit
work
public
gfg
lead
princip
investig
nation
natur
scienc
foundat
china
innov
research
group
grant
conflict
interest
